Curis Announces Key Management Addition
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sept. 3, 2002--Curis, Inc. (NASDAQ: CRIS - News) announced that Elizabeth Potthoff, Esq., has accepted the position of Vice President, General Counsel. Ms. Potthoff is an important addition to the Curis executive management team and brings more than twenty years of business and legal experience in the corporate world. She was most recently Vice President, General Counsel and Corporate Secretary at Wheelhouse Corporation in Burlington, MA. Prior to that, she served as Vice President, General Counsel and Corporate Secretary at Shiva Corporation in Bedford, MA and Senior Corporate Counsel at Bytex Corporation in Westboro, MA. Previous experience includes positions in Legal and Finance at Prime Computer in Natick, MA and Wang Labs in Lowell, MA. Ms. Potthoff received her J.D., cum laude, from Suffolk University, an M.B.A. from Providence College, and a B.A. from the State University of New York.
"Ms. Potthoff's corporate experience and legal management of public companies will make her an extremely important addition to the Curis executive team," said Daniel R. Passeri, President and Chief Executive Officer. "As Curis evolves, her experience will prove invaluable to protecting and developing our intellectual property portfolio. Ms. Potthoff possesses the ideal background to oversee our legal department, protect our intangible assets, and add sound legal expertise to our management team."
About Curis, Inc.
Curis, Inc. is generating therapies that regulate the pathways used by the body to maintain and restore health. The company focuses on signaling pathways that govern the proliferation and differentiation of cells. These same pathways control maintenance, repair, and regeneration of tissues and organs from infancy through old age. This approach has created an approved product for bone regeneration and enables Curis to build a portfolio of product candidates in neurology, kidney disease, and cancer. For more information, please visit the Curis web site at www.curis.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The matters discussed in this press release involve risks and uncertainties that may cause Curis' actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: Curis' need for partnerships to move forward its cell therapy programs, the early stage of product development of Curis' retained programs, uncertainties related to clinical trials, uncertainties related to Curis' ability to raise additional capital, changes in or an inability to execute Curis' realigned business strategy and other risk factors described from time to time in Curis' periodic reports and registration statements filed with the Securities and Exchange Commission, including, without limitation, Curis' Annual Report on Form 10-K for the year ended December 31, 2000 filed on March 30, 2001 and the Company's Post Effective Amendment No. 1 on Form S-3 to the Registration Statement on Form S-1 filed with the Securities and Exchange Commission on August 10, 2001. Curis cannot guarantee any future results, levels of activity, performance, or achievements. Moreover, neither Curis nor anyone else assumes responsibility for the accuracy and completeness of any forward-looking statements. Curis undertakes no obligation to update any of the forward-looking statements after the date of this press release.
--------------------------------------------------------------------------------
Contact:
Curis, Inc.
Henry W. McCusker, 617/503-6641
or
Noonan Russo Presence
Sharon Weinstein, 212/845-4271
--------------------------------------------------------------------------------
Source: Curis, Inc. |
